10:05 AM EDT, 08/11/2025 (MT Newswires) -- Viatris ( VTRS ) said Monday that the US Food and Drug Administration has approved its iron sucrose injection for the treatment of iron deficiency anemia in adult and pediatric patients with chronic kidney disease.

The company said the intravenous iron replacement product is the first approved generic version of Venofer injection and is expected to be available "imminently."

Viatris ( VTRS ) also said the FDA granted a competitive generic therapy designation to the iron sucrose injection, in doses of 100 milligram/5 milliliter and 200 mg/10 mL. The designation helps expedite the review process for generic versions of drugs with "inadequate generic competition," according to Viatris ( VTRS ).

Shares of were up more than 3% in recent trading Monday.

Price: 10.04, Change: +0.34, Percent Change: +3.51